Assessing the influence of different validation protocols on Ocean Colour match-up analyses

Abstract Multiple approaches have been used by the Ocean Colour community for validating satellite-derived products using in situ data, with most of them derived from mainly two approaches, one suggested by Bailey and Werdell (2006) (BW06) and one suggested by Zibordi et al. (2009a) (Z09), each with a different set of quality checking and spatiotemporal collocation criteria. The question remains what sort of information is added or missed when choosing one over the other. In this work, the differences among validation approaches were determined by using a common dataset of in situ and satellite data. The match-up exercise was separated into two groups of datasets based on the spatial resolution of the sensors to be validated. Sentinel-3A/OLCI data were selected as a representation of medium spatial resolution sensors, and two validation approaches were selected to this match-up dataset. The high spatial resolution sensors were represented by Sentinel-2A/MSI data, and three validation approaches were tested. Data from the AERONET-OC network were chosen as the common in situ dataset. For Sentinel-3A/OLCI, the number of match-ups varies depending on the validation approach used. Bailey and Werdell (2006) produces 20% more match-ups for Sentinel-3A/OLCI due to its more relaxed filtering criteria compared to the criteria applied by Zibordi et al. (2009a) . The validation metrics vary between different validation methods giving a different impression of accuracy of the satellite products. Also, the satellite data selected by BW06 have a statistical distribution with a higher median and standard deviation when compared to Z09. Similar findings are also confirmed for the match-up analysis conducted for Sentinel-2A/MSI. Therefore, although a common reference dataset was used, the validation statistical results were influenced by the validation approach selected. This does not suggest that one validation protocol is better than the other, but it implies that validation statistics reported in different studies may not always be directly comparable. Additionally, it was determined that BW06 could be a better fit when trying to obtain a sufficient number of match-ups for calibration purposes in the shortest time

Using overlapping VIIRS scenes to observe short term variations in particulate matter in the coastal environment

Abstract In coastal areas, the concentrations and the optical properties of the water components have a large spatial and temporal variability, due to river discharges and meteo-marine conditions, such as wind, wave and current, and their interaction with shallow water bathymetry. This large temporal variability cannot be captured using the standard Ocean Colour Radiometry (OCR) polar orbiting satellites, the latter providing almost one image per day. On the contrary, the use of OCR geostationary sensors, like the Geostationary Ocean Colour Imager (GOCI), centred above the Korean Peninsula, enable to capture the short-term variability of the optical properties. To compensate the lack of a geostationary sensor similar to GOCI over other coastal environments, like the North Adriatic Sea (NAS), the multiple observations provided during the same day by the Visible Infrared Imaging Radiometer Suite (VIIRS) mounted on the SUOMI NPP satellite, can be exploited. Indeed, due to its large swath of 3060 km, the VIIRS orbits can overlap over the NAS during the same day within 1 h and 42 min, an important feature that can be useful in capturing the short term variability of the optical properties. A large number of VIIRS overlaps in the NAS are characterized by high sensor zenith angle (SZA) of the observation, resulting in a large portion of images masked by the high satellite zenith flag. In order to make available those observations and, in general, to reduce the dependence of the VIIRS observations from the SZA, an adjustment based on a multi linear regression scheme, which exploits radiometric in situ observations, was here applied. This study aims to prove the suitability of the adjusted overlapping VIIRS in capturing the short time scale dynamics of particulate backscattering, and this was demonstrated by the analysis of a case study for the 21st and 22nd of March 2013. In order to evaluate the advantages in using multiple observations during the same day, also the ~24 h dynamics was analysed, comparing the overlapping VIIRS results with the ones obtained from the daily product

ANCA-associated vasculitis in childhood: Recent advances

Abstract Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare systemic diseases that usually occur in adulthood. They comprise granulomatosis with polyangiitis (GPA, Wegener’s), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome). Their clinical presentation is often heterogeneous, with frequent involvement of the respiratory tract, the kidney, the skin and the joints. ANCA-associated vasculitis is rare in childhood but North-American and European cohort studies performed during the last decade have clarified their phenotype, patterns of renal involvement and their prognostic implications, and outcome. Herein, we review the main clinical and therapeutic aspects of childhood-onset ANCA-associated vasculitis, and provide preliminary data on demographic characteristics and organ manifestations of an Italian multicentre cohort

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis

Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs in juvenile idiopathic arthritis (JIA), and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on systemic JIA (sJIA). This study aims to describe IL-1 inhibitors DRR and evaluate predictive factors of drug survival based on data from a real-world setting concerning sJIA.Methods: Medical records from sJIA patients treated with anakinra (ANA) and canakinumab (CAN) were retrospectively analyzed from 15 Italian tertiary referral centers.Results: Seventy seven patients were enrolled for a total of 86 treatment courses. The cumulative retention rate of the IL-1 inhibitors at 12-, 24-, 48-, and 60-months of follow-up was 79.9, 59.5, 53.5, and 53.5%, respectively, without any statistically significant differences between ANA and CAN (p = 0.056), and between patients treated in monotherapy compared to the subgroup co-administered with conventional immunosuppressors (p = 0.058). On the contrary, significant differences were found between biologic-naive patients and those previously treated with biologic drugs (p = 0.038) and when distinguishing according to adverse events (AEs) occurrence (p = 0.04). In regression analysis, patients pre-treated with other biologics (HR = 3.357 [CI: 1.341-8.406], p = 0.01) and those experiencing AEs (HR = 2.970 [CI: 1.186-7.435], p = 0.020) were associated with a higher hazard ratio of IL-1 inhibitors withdrawal. The mean treatment delay was significantly higher among patients discontinuing IL-1 inhibitors (p = 0.0002).Conclusions: Our findings suggest an excellent overall DRR for both ANA and CAN that might be further augmented by paying attention to AEs and employing these agents as first-line biologics in an early disease phase

Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): An international survey

Background: Following the Coronavirus Disease-19 (COVID-19) pandemic outbreaks, the hyperinflammatory condition termed Multisystem Inflammatory Syndrome in Children (MIS-C) became a healthcare issue worldwide. Since December 2020 the mRNA vaccine against SARS-CoV-2 has become available with a good safety profile. However, evidence regarding safety and vaccination strategies in children with previous MIS-C is still lacking. The aim of our study was to investigate the current approach of international centers to anti-SARS-CoV-2 and other vaccinations in children with a history of MIS-C. Methods: Physicians who care for patients with MIS-C were invited to anonymously complete a 15-question, web-based survey. The survey was open from October 6 to December 31, 2021. Results: A total of 290 replies from 236 centers in 61 countries were collected. Most respondents (86%) were pediatric rheumatologists. The anti-SARS-CoV-2 vaccine was available in 85% of the countries. Sixty-seven centers (28%) in 22 countries already vaccinated MIS-C patients without adverse reactions in most cases (89%). Six reported complications: 2 not specified, 3 mild symptoms and 1 reported a MIS-C-like reaction. Most centers (84%) favored vaccinating MIS-C patients against SARS-CoV-2, after 3–6 months (40%), 6–12 months (52%) or >12 months (8%). The survey revealed broad heterogeneity of responses among healthcare providers within the same country and within the same center. The variable with the greatest impact on the decision not to vaccinate MIS-C patients was the current lack of evidence (51%), followed by patient/parent objection (40%). The most relevant parameters in the vaccination strategy were time from MIS-C episode (78%), immunosuppressive treatment (35%), SARS-CoV-2 serologic status (32%), and MIS-C features (31%). Almost all centers favored continuing regular vaccination with non-live (99%) and live (93%) vaccines; however, with high variability in suggested timelines. Conclusion: To date, the experience of the international pediatric rheumatology community in vaccinating MIS-C patients against SARS-CoV-2 is overall reassuring. However, lack of evidence causes broad heterogeneity in vaccination strategy worldwide

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis : 1-year followup data from the Italian Registry

To evaluate safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of juvenile idiopathic arthritis-related anterior uveitis (JIA-AU).Starting January 2007, patients with JIA-AU treated with IFX and ADA were managed by a standard protocol and data were entered into the National Italian Registry (NIR). At baseline, all patients were refractory to standard immunosuppressive treatment and/or were corticosteroid-dependent. Data recorded every 3 months included uveitis course, number/type of ocular complications, drug-related adverse events (AE), treatment change or withdrawal, and laboratory measures. Data of patients treated for at least 1 year were retrieved from the NIR and analyzed using descriptive statistics. Treatment efficacy was based on change in uveitis course and in number of ocular complications.Up to December 2009, data for 108 patients with JIA-AU treated with anti-tumor necrosis factor-\u3b1 agents were recorded in the NIR and data from 91, with at least 12 months' followup, were included in the study. Forty-eight patients were treated with IFX, 43 with ADA. Forty-seven patients (55.3%) achieved remission of AU, 28 (32.9%) had recurrent AU, and 10 (11.8%) maintained a chronic course. A higher remission rate was observed with ADA (67.4% vs 42.8% with IFX; p = 0.025). Ocular complications decreased from 0.47 to 0.32 per subject. Five patients experienced resolution of structural complications. No patient reported serious AE; 8 (8.8%) experienced 11 minor AE (9 with IFX, 2 with ADA).IFX and ADA appear to be effective and safe for treatment of refractory JIA-related uveitis, with a better performance of ADA in the medium-term period

Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care

Introduction: This study aimed to address therapeutic inertia in the management of type 2 diabetes (T2D) by investigating the potential of early treatment with oral semaglutide. Methods: A cross-sectional survey was conducted between October 2021 and April 2022 among specialists treating individuals with T2D. A scientific committee designed a data collection form covering demographics, cardiovascular risk, glucose control metrics, ongoing therapies, and physician judgments on treatment appropriateness. Participants completed anonymous patient questionnaires reflecting routine clinical encounters. The preferred therapeutic regimen for each patient was also identified. Results: The analysis was conducted on 4449 patients initiating oral semaglutide. The population had a relatively short disease duration (42%  60% of patients, and more often than sitagliptin or empagliflozin. Conclusion: The study supports the potential of early implementation of oral semaglutide as a strategy to overcome therapeutic inertia and enhance T2D management

S-shaped brachioplasty: An effective technique to correct excess skin and fat of the upper arm

No Abstract availabl

SMAS strip autograft

The thinning of the overlying nasal skin and nasal SMAS layer and the variations in nasal bones consistency increase the risk of showing dorsal contour irregularities after osteotomies of this site. The authors present their experience with combined nasal dorsal osteotomies and insertion of a SMAS strip graft, harvested during facelift procedure in 6 aging patients. Postoperative follow-up time ranged from 1 year to 7 years and showed excellent outcomes: no infection, graft migration, or reabsorption was detected. Due to the ease of execution of the procedure and taking into account this graft as an ideal soft-tissue augmentation composed by fat, muscle, and fascia, the SMAS strip autograft represents another viable option for nasal dorsum contouring in the patient presenting also for rhythidectomy. Copyright \ua9 2013 by Mutaz B. Habal, MD